334 related articles for article (PubMed ID: 24079771)
21. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain.
Kuhad A; Singh P; Chopra K
Expert Opin Ther Targets; 2015 Feb; 19(2):177-85. PubMed ID: 25243524
[TBL] [Abstract][Full Text] [Related]
22. Targeting Matrix Metalloproteinases for Diabetic Retinopathy: The Way Ahead?
Solanki A; Bhatt LK; Johnston TP; Prabhavalkar KS
Curr Protein Pept Sci; 2019; 20(4):324-333. PubMed ID: 30215334
[TBL] [Abstract][Full Text] [Related]
23. Role of Matrix Metalloproteinases in Angiogenesis and Its Implications in Asthma.
Bajbouj K; Ramakrishnan RK; Hamid Q
J Immunol Res; 2021; 2021():6645072. PubMed ID: 33628848
[TBL] [Abstract][Full Text] [Related]
24. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
Chen Y; Peng W; Raffetto JD; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
[TBL] [Abstract][Full Text] [Related]
25. Metalloproteinases and their inhibitors in tumor angiogenesis.
Handsley MM; Edwards DR
Int J Cancer; 2005 Jul; 115(6):849-60. PubMed ID: 15729716
[TBL] [Abstract][Full Text] [Related]
26. Metalloproteinases and their inhibitors in neurological disease.
Lopez-Navarro ER; Gutierrez J
Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):27-38. PubMed ID: 34851449
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis.
Pohl M; Sakurai H; Bush KT; Nigam SK
Am J Physiol Renal Physiol; 2000 Nov; 279(5):F891-900. PubMed ID: 11053050
[TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology.
de Almeida LGN; Thode H; Eslambolchi Y; Chopra S; Young D; Gill S; Devel L; Dufour A
Pharmacol Rev; 2022 Jul; 74(3):712-768. PubMed ID: 35738680
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
30. Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges.
Zipfel P; Rochais C; Baranger K; Rivera S; Dallemagne P
J Med Chem; 2020 Oct; 63(19):10705-10725. PubMed ID: 32459966
[TBL] [Abstract][Full Text] [Related]
31. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.
Yang H; Khalil RA
Adv Pharmacol; 2022; 94():255-363. PubMed ID: 35659374
[TBL] [Abstract][Full Text] [Related]
32. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies.
Itoh Y
Prog Mol Biol Transl Sci; 2017; 148():327-338. PubMed ID: 28662826
[TBL] [Abstract][Full Text] [Related]
33. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
34. Metalloproteinases and their inhibitors in angiogenesis.
Lafleur MA; Handsley MM; Edwards DR
Expert Rev Mol Med; 2003 Sep; 5(23):1-39. PubMed ID: 14585170
[TBL] [Abstract][Full Text] [Related]
35. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases in neuroinflammation.
Rosenberg GA
Glia; 2002 Sep; 39(3):279-91. PubMed ID: 12203394
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory role of metalloproteases in cancers: Current progress and future trends.
Wang Q; Wang K; Tan X; Li Z; Wang H
Front Immunol; 2022; 13():1064033. PubMed ID: 36591235
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase inhibition in atherosclerosis and stroke.
Roycik MD; Myers JS; Newcomer RG; Sang QX
Curr Mol Med; 2013 Sep; 13(8):1299-313. PubMed ID: 23865428
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
40. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis.
Milner JM; Rowan AD; Cawston TE; Young DA
Arthritis Res Ther; 2006; 8(5):R142. PubMed ID: 16919164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
